A new study published in Profiles of Drug Substances, Excipients and Related Methodology stated that isotretinoin – (2Z, 4E, 6E, 8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid, is an orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. It acts primarily by reducing sebaceous gland size and sebum production, and as a result alters skin surface lipid composition.

The authors confirmed that isotretinoin for 1-2mg/kg/day for 3-4 months produces 60-95% clearance of inflammatory lesions in patients with acne. Doses as low as 0.1mg/kg/day have also proven successful in the clearance of lesions. In addition, encouraging results have also been seen in small numbers of patients with rosacea.

Side effects affecting the mucocutaneous system and raised serum triglyceride levels occur in most patients receiving isotretinoin.The article further reported that isotretinoin is contraindicated in women of childbearing potential.

Source: Profiles of Drug Substances, Excipients and Related Methodology.2020;45:119-157.doi: 10.1016/bs.podrm.2019.10.005.